Patients taking GLP-1 drugs reduce their snacking and alcohol consumption, but the overall impact on the restaurant industry will be minimal, Allan Hickok, senior advisor at the Boston Consulting Group, tells Bloomberg Intelligence. In this episode of the Choppin’ It Up podcast, Hickok sits down with BI’s senior restaurant and foodservice analyst Michael Halen to discuss how the drugs are affecting consumer behavior. He also commented on generative AI, loyalty programs and menu pricing.

See omnystudio.com/listener for privacy information.